Business
The startup plans to use the funds to expand nationwide, add virtual primary care services and get its offerings covered by insurers.
Formerly known as IDx, the company received FDA De Novo clearance in 2018 for its IDx-DR system used to detect diabetic retinopathy.
UnitedHealth Group, CVS and Option Care Health are also in the running, reports say.
The newly public company, now trading on Nasdaq under the ticker symbol "AKLI," will use the proceeds from the transaction to launch EndeavorRx, its video game-like digital therapeutic for children with ADHD.
It will be used to accelerate collaborations with pharmaceutical firms.
It will use its latest funds for its global expansion.
Also, CureApp is getting $77 million in investment from the Sawai Group as part of their license deal.
The new funds will be used to support the rollout of its hypertension DTx app.
The startup connects new mental health providers with supervisors to complete their licensure requirements. The new funding brings its total raise to $16.3 million.
It is now preparing for a Series A fundraising round in the next six months.